Answers are grounded in this paper and cite their sources.
The Food and Drug Administration has proposed allowing public health considerations to be factored into drug-approval decisions for opioids. It may already be possible, however, for the agency to use labeling changes to affect marketing and promotion.
No takes yet. Share an insight, caveat, or question.
Psaty et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: